Neurocentrum Bydgoszcz Sp. z o.o.

Bydgoszcz 32 trials 14 recruiting

32 Registered trials

14 Currently recruiting

Organisation

Neurocentrum Bydgoszcz Sp. z o.o.

Location

Bydgoszcz, Poland

Identifier

ORG-100046522

Address

Ul. Aleje Prof. Sylwestra Kaliskiego 28/U1, 85-796, Poland

Departments

-
#5806
1901
2601
40840: Neurocentrum
4104
MS Treatment Clinic
N/A
NA
NA / ND
Neurocentrum Bydgoszcz Sp. z o.o. (#1)
Neurology

Clinical trials at this site (32)

Search interface

A study to assess efficacy and safety of empasiprubart versus IVIg in adults with CIDP ("emvigorate") Recruiting

2024-520097-36-00 Chronic inflammatory demyelinating polyneuropathy (CIDP 5 2026-01-07
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting

2024-512126-29-00 Generalized Myasthenia Gravis 5 2025-02-25
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis Recruiting

2024-512707-40-00 RELAPSING MULTIPLE SCLEROSIS 4 2024-11-07
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 multiple sclerosis 5 2024-10-17
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients with P… Recruiting

2024-514617-35-00 Progressive forms of Multiple Sclerosis 4 2021-12-20
Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU-838 on disease activity, as measured by … Recruiting

2024-516739-29-00 Relapsing-remitting multiple sclerosis 4 2019-01-23
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site… Recruiting

2025-523757-33-00 multiple sclerosis 4 2026-05-07
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
A study to compare different doses of RO7268489 with a placebo (as add-on therapy to ocrelizumab) in people with multiple sclerosis that has… Recruiting

2025-521636-10-00 Progressive Forms of Multiple Sclerosis (PMS) 4 2026-02-04
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis Recruiting

2024-517980-22-00 Multiple Sclerosis (MS) 4 2025-12-10
Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting

2024-519284-18-00 Relapsing multiple sclerosis 5 2025-06-18
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient… Recruiting

2023-510026-32-00 Generalized Myasthenia Gravis 5 2025-06-11
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Recruiting

2023-504152-97-00 Generalized Myasthenia Gravis 5 2021-11-26
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
Comparative PK, PD, efficacy, safety and immunogenicity assessment of the proposed ocrelizumab biosimilar CYB704 and Ocrevus in participants… Ended

2024-512319-40-00 Subjects with relapsing multiple sclerosis (relapsing r 5 2025-07-01
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
A study to learn if Rozanolixizumab works and is safe over a long period in adults with relapsing myelin oligodendrocyte glycoprotein antibo… Ended

2023-509237-39-00 Myelin oligodendrocyte glycoprotein antibody-associated 5 2022-08-02
Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat… Ended

2023-509345-12-00 Multiple Sclerosis 5 2022-06-22
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients with Myelin Oligodendrocyte Gly… Ended

2023-507196-22-00 Myelin Oligodendrocyte Glycoprotein Antibody-Associated 5 2022-06-20
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared with Ocrelizumab in Adult Patients with Primary Progressive Multiple Sc… Ended

2022-502611-10-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-11-24
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sc… Ended

2023-506515-18-00 Primary Progressive Multiple Sclerosis (PPMS) 5 2020-10-23
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults with Relapsing Multiple Sclerosis Ended

2023-506467-34-00 Relapsing Multiple Sclerosis (MS) 5 2020-10-20
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults with Primary Progressive Multiple Sclerosis Ended

2023-505980-36-00 Primary progressive multiple sclerosis (PPMS) 5 2019-09-19